ClinicalTrials.gg

Program

vilzemetkib

Also written as “AL2846 capsule”, “AL2846 capsules” and “AL2846”.

In Sino Biopharmaceutical's pipeline, AXL/MET酪氨酸激酶抑制剂. Its studies are mostly in Thyroid Neoplasms · Ovarian Neoplasms · Neurofibromatoses · Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Sino Biopharmaceutical.

Furthest: phase 3, since Feb 24, 20258 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical82 open or runningphase 3since Feb 24, 2025May 16, 2016Jan 2027phase 3 · NCT06860971
  • Named in Sino Biopharmaceutical’s own pipeline as AL2846, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 16, 2016First study: phase 1 study in Advanced CancerFirst studyNCT02779699 · 20 enrolled · China
  2. Mar 25, 2020Phase 2 study in Bone Metastatic Non-small Cell Lung CancerNCT04325776 · 60 enrolled · China
  3. Aug 10, 2021Phase 2 study in NeurofibromatosesNCT05011019 · 22 enrolled · China
  4. Feb 16, 2023Phase 2 study in Differentiated Thyroid CancerNCT05745363 · 33 enrolled · China
  5. Apr 4, 2023Phase 2 study in Ovarian NeoplasmsNCT05815862 · 29 enrolled · China
  6. Oct 31, 2023Phase 1 study in Solid TumorNCT06116240 · 135 enrolled · China
  7. Feb 19, 2024Phase 2 study in Pancreatic NeoplasmsNCT06278493 · 34 enrolled · China
  8. Feb 24, 2025Phase 3 study in Thyroid NeoplasmsNCT06860971 · 144 planned · China

Ahead

  1. Jan 2027Primary completion: phase 3 study in Thyroid NeoplasmsNCT06860971

TargetBeta

“AXL/MET酪氨酸激酶抑制剂”the company's pipeline, read by Claude · source
“An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
zanzalintinibruleExelixisphase 317

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06860971Thyroid Neoplasms · China3RecruitingJan 2027144
NCT06278493Pancreatic Neoplasms · China2CompletedOct 25, 202134
NCT06116240Solid Tumor · China1Active, not recruitingDec 2023135
NCT05815862Ovarian Neoplasms · China2CompletedAug 20, 202529
NCT05745363Differentiated Thyroid Cancer · China2CompletedNov 13, 202533
NCT05011019Neurofibromatoses · China2TerminatedFeb 2, 202422
NCT04325776Bone Metastatic Non-small Cell Lung Cancer · China2UNKNOWNMay 202160
NCT02779699Advanced Cancer · China1UNKNOWNOct 202020

How it is read

Names in the registry

  • “AL2846 capsule”, 3 entries
  • “AL2846 capsules”, 2 entries
  • “AL2846”, 2 entries
  • “AL2846 Capsules”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.